MedPath

Stem Cells Treatment of Complex Crohn's Anal Fistula

Not Applicable
Completed
Conditions
Anal Fistula
Crohn Disease
Interventions
Procedure: stem cells injection
Registration Number
NCT03466515
Lead Sponsor
University of Southern Denmark
Brief Summary

A pilot study to investigate the safety and feasibility of stem cells treatment of complex anal fistula in patients with Crohn's disease.

Detailed Description

Stem cells therapy in the management of soft tissue healing has been shown to be safe and feasible with encouraging short-term results both for crypto glandular and Crohns anal fistula. The long-term results are still insufficient but based on only a few studies conducted with small patient series and various techniques and type of stem cells. In the present study the patient's own adipose tissue derived regenerative cells (ADRCs) will be used. Traditionally the stem cells are injected into the fistula tract; however survival and retaining the stem cells in the fistula tract is problematic. Alternatively, one may apply stem cells enriched fatty tissue around and into the fistula tract. The aim of this project is to develop a method for treatment of patients with Crohns fistula. The results of conventional surgery are disappointing and followed by a high degree of recurrence and complications.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • patients with Crohn's anal fistulas and> 18 yrs old.
Exclusion Criteria
  • Signs of suppuration around the fistula
  • Active intestinal Crohn disease not in remission
  • Malignancy within 5 years
  • Previous radiotherapy of the abdomen and pelvis
  • BMI under 18.5
  • Coagulopathy
  • Fistula with side branches
  • Low anal fistula
  • Verified syphilis, HIV, or hepatitis on screening test.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
interventionstem cells injectionPatients enrolled in the study will be treated for their anal fistula by surgical closure of the internal opening, debridement of the fistula and injection of patients own stem cells enriched fatty tissue around the fistula.
Primary Outcome Measures
NameTimeMethod
healing6 months

closure of the fistula with no secretions

Secondary Outcome Measures
NameTimeMethod
recurrence6 months

recurrence of the fistula

time to healing6 months

time required to healing of the fistula

radiological healingat 6 months

Changes on MRI scanning

functional outcome6 months

changes in Wexner incontinence score

major adverse effects6 months

occurrence of infections, sepsis bleeding and allergy.

Trial Locations

Locations (1)

Odense University Hospital

🇩🇰

Odense, Denmark

© Copyright 2025. All Rights Reserved by MedPath